Welcome to our dedicated page for Precigen SEC filings (Ticker: PGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Precigen, Inc. (PGEN) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Precigen is a Nasdaq Global Select Market–listed biopharmaceutical company, and its filings offer detailed insight into the commercialization of PAPZIMEOS for recurrent respiratory papillomatosis (RRP), ongoing clinical programs, capital structure, and material agreements.
Current reports on Form 8-K document key corporate events, such as the announcement of financial results, entry into material definitive agreements, and capital transactions. For example, recent 8-K filings describe a senior secured term loan facility of up to $125 million with entities managed by Pharmakon Advisors, LP, a commercial supply agreement for PAPZIMEOS with an external manufacturing partner, and the conversion of Series A Convertible Perpetual Preferred Stock into common stock. Other 8-Ks cover shareholder meeting results, including approvals of equity incentive plan amendments and increases in authorized common shares.
Periodic reports such as annual and quarterly filings (Forms 10-K and 10-Q, when available) provide broader context on Precigen’s financial condition, risk factors, research and development activities, and commercialization efforts. These documents typically include discussions of PAPZIMEOS approval and launch, the company’s pipeline programs like PRGN-2009 and PRGN-3006, and the impact of financing arrangements and warrant liabilities on the balance sheet.
Investors can also review any Form 4 or related insider transaction filings, when present, to understand equity transactions by directors, officers, or significant shareholders. On Stock Titan, AI-powered tools summarize complex filings, highlight key terms in loan and supply agreements, and help explain the implications of capital structure changes, regulatory milestones, and other material events disclosed in Precigen’s SEC submissions.
PRECIGEN, INC. director and 10% owner Randal J. Kirk reported multiple indirect open-market sales of Common Stock through entities he controls. In total, these entities sold 4,772,781 shares at a weighted average price of $3.30 per share in transactions on March 30, 2026, with individual prices ranging from $3.22 to $3.58.
The sales were made by vehicles including R.J. Kirk Declaration of Trust, various JPK, MGK and ZSK LLCs, the Kellie L. Banks (2009) Long Term Trust and Sunset 2020, LLC. After the transactions, reported indirect holdings included 80,672,818 shares by R.J. Kirk Declaration of Trust and 12,262,741 shares by Sunset 2020, LLC, along with additional positions at entities such as Kapital Joe, Lotus, Third Security and Parkview 2020. Mr. Kirk may be deemed to beneficially own these shares under Rule 13d-3 but disclaims beneficial ownership except to the extent of any pecuniary interest.
Precigen, Inc. major holder Randal J. Kirk and affiliated entities disclosed open-market sales of 4,772,781 shares of Common Stock on March 30, 2026, generating aggregate net proceeds of approximately $15,581,221. After these sales, Mr. Kirk reports beneficial ownership of 133,956,416 shares, or 35.9% of the company’s Common Stock, including 988,659 options and 16,666,667 warrants that are exercisable within sixty days. The R.J. Kirk Declaration of Trust reports 97,339,485 shares, or 26.1%, including 16,666,667 warrants, while Third Security, LLC reports 21,843,458 shares, or 5.9%. Percentage ownership is calculated using 353,928,672 shares outstanding as of February 15, 2026, adjusted for subsequent equity grants, vested restricted stock units, and Mr. Kirk’s exercisable options and warrants.
PGEN filed a Form 144 reporting proposed sales of Common Stock. The filing lists historical issuances, private placements, RSU vesting events and a secondary public offering with per-event share counts and dates from 03/01/2013 through 07/03/2018.
Precigen, Inc. presents an annual overview as a newly commercial-stage biopharmaceutical company following full FDA approval of Papzimeos for adults with recurrent respiratory papillomatosis. In a pivotal study, 51% of 35 patients at the recommended dose achieved a complete response with durable benefit beyond 12 months.
The company estimates about 27,000 adults in the United States live with this disease and has launched Papzimeos with broad U.S. payer coverage, including approximately 215 million privately insured lives plus Medicare and Medicaid. Beyond Papzimeos, Precigen advances its AdenoVerse immunotherapy and UltraCAR-T platforms, while pausing some early UltraCAR-T trials to focus resources on lead programs.
Precigen reported a pivotal 2025 as it shifted to a commercial-stage model following FDA approval and US launch of PAPZIMEOS for recurrent respiratory papillomatosis. Total revenues were $9.7 million for the year, up from $3.9 million in 2024, driven by $3.4 million of PAPZIMEOS product revenue and higher collaboration and licensing revenue of $1.8 million.
Research and development expenses fell to $41.3 million, a $11.7 million decrease tied to pipeline prioritization and the ActoBio shutdown, while selling, general and administrative costs rose to $70.1 million as the company invested in PAPZIMEOS commercial readiness and launch. Operating loss improved modestly to $110.5 million.
Other non-operating items dominated the bottom line. A $139.5 million increase in the fair value of warrant liabilities and a $179.0 million non-cash deemed dividend on preferred stock led to a net loss attributable to common shareholders of $429.6 million, or $1.37 per share, compared with $126.2 million, or $0.47 per share, in 2024. As of December 31, 2025, cash and cash equivalents were $30.2 million and short-term investments were $67.6 million. Management expects the current cash position and PAPZIMEOS sales to fund operations through cash flow break-even by the end of 2026.
PRECIGEN, INC. Chief Financial Officer Harry Thomasian Jr. received a grant of 40,293 restricted stock units on March 18, 2026. Each RSU represents a contingent right to receive one share of Precigen common stock and the RSUs vested immediately upon grant. He then exercised the RSUs into 40,293 shares of common stock at a conversion price of $0.00 per share, bringing his directly held common stock position to 508,919 shares.
PRECIGEN, INC. Chief Commercial Officer Phil Tennant received a grant of 42,110 restricted stock units on March 18, 2026. Each RSU represents one share of common stock and vested immediately on the grant date. The RSUs were then exercised and converted into 42,110 shares of common stock at no cash exercise price, increasing his directly owned common stock holdings to 107,141 shares after these transactions. These actions reflect compensation-related equity awards and derivative exercises, not open-market buying or selling.
PRECIGEN, INC. President and CEO Helen Sabzevari received a grant of 321,100 restricted stock units on March 18, 2026, each representing one share of common stock. The RSUs vested immediately on the grant date as part of her equity compensation.
She then exercised these 321,100 RSUs at $0.00 per unit, converting them into 321,100 shares of common stock. Following the transactions, she directly holds 3,638,122 shares of Precigen common stock. These are compensation-related acquisitions, not open-market purchases.
PRECIGEN, INC. Chief Operating Officer Rutul R. Shah reported equity compensation activity in the form of restricted stock units (RSUs). On March 18, 2026, he received a grant of 44,495 RSUs, each representing one share of common stock, which vested immediately at a price of $0.00 per unit. These RSUs were then exercised and settled into 44,495 shares of Precigen common stock, increasing his direct common stock holdings to 450,454 shares following the transactions.
PRECIGEN, INC. Chief Legal Officer Donald P. Lehr reported a compensation-related equity transaction involving restricted stock units (RSUs). On March 18, 2026, he received a grant of 40,443 RSUs, each representing a contingent right to one share of common stock, at a stated price of $0.0000 per unit.
The footnotes state that these RSUs vested immediately on the grant date. On the same date, Lehr exercised the 40,443 RSUs, converting them into 40,443 shares of common stock at an exercise price of $0.0000. Following this exercise, his directly held common stock position increased to 722,092 shares, and no remaining derivative position is shown in this filing.
This sequence reflects an RSU grant and immediate vesting-and-exercise rather than an open-market purchase or sale, making it a routine equity compensation event for a senior executive.